chartexchange

Medunik USA reaffirms commitment to UCD patients with continued availability of Pheburane® (sodium phenylbutyrate)

PR Newswire | Oct 28, 2026 7:32 AM EDT

PRINCETON, N.J., Oct. 28, 2026 /PRNewswire/ -- Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay Pharmaceutical Group (DPG), is pleased to reaffirm that as the treatment landscape for urea cycle...

Read original article